LUND, Sweden, Oct. 29, 2021 /PRNewswire/ -- Immunovia will publish the company's interim report for the period January 1 - September 30, 2021 on Thursday, November 11, 2021 at 16:00 CET. Investors, analysts and media are invited to a telephone conference with web presentation on the same day at 16:30 CET.

CEO Patrik Dahlen will present Immunovia and comment on the interim report followed by a Q&A session. The webcasted telephone conference will be held in English.

To participate in the telephone conference, please call:

Sweden: +46 8 505 583 52
United Kingdom: +44 333 300 92 73
United States: +1 646 722 49 57
Belgium: +32 262 005 47
Denmark: +45 787 232 51
France: +33 170 750 719
Germany: +49 692 222 391 65
Norway: +47 239 636 88
Switzerland: +41 225 805 976
Netherlands: +31 207 219 496

Link to the webcast:

Following the telephone conference, a recording will be available on Immunovia's website (

For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64

About Immunovia

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1.

In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: The European launch plan will be communicated during the second half of 2021.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit

This information was brought to you by Cision,c3443310

The following files are available for download:

Press release (PDF)

Cision View original content:

SOURCE Immunovia AB

Copyright 2021 PR Newswire

Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022 Haga Click aquí para más Gráficas Immunovia Ab (publ).
Immunovia Ab (publ) (LSE:0G8X)
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022 Haga Click aquí para más Gráficas Immunovia Ab (publ).